Neurocrine Biosciences Inc (NBIX) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorder...
Neurocrine Biosciences Inc's revenue increased 21.4% year over year, from $2.36B to $2.86B.
Net income increased 40.2% over the same period, from $341.3M to $478.6M.
Operating cash flow grew 31.5% to $782.7M.
Neurocrine Biosciences Inc maintains a healthy net profit margin of 16.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $590.2M+14.5% | $65.0M | $581.0M | $145.4M | $64.6M | $3.31B | N/A | $2.51B |
| Q3 FY2024 | $622.1M+5.4% | $129.8M | $614.1M | $183.8M | $158.0M | $3.54B | N/A | $2.72B |
| Q4 FY2024 | $627.7M+0.9% | $103.1M | $618.4M | $142.0M | $242.5M | $3.72B | N/A | $2.59B |
| Q1 FY2025 | $572.6M-8.8% | $7.9M | $563.4M | $23.6M | $64.8M | $3.69B | N/A | $2.54B |
| Q2 FY2025 | $687.5M+20.1% | $107.5M | $676.2M | $145.6M | $102.0M | $3.89B | N/A | $2.69B |
| Q3 FY2025 | $794.9M+15.6% | $209.5M | $780.9M | $239.0M | $227.5M | $4.27B | N/A | $3.00B |
| Q4 FY2025 | $805.5M+1.3% | $153.7M | $787.9M | $210.9M | $388.4M | $4.63B | N/A | $3.25B |
| Q1 FY2026 | $814.5M+1.1% | $197.9M | $800.7M | $193.4M | $145.8M | $4.91B | N/A | $3.41B |
Balance Sheet Summary (Latest Period)
Neurocrine Biosciences Inc (NBIX) Financial Statements & Revenue History
Neurocrine Biosciences Inc (NBIX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $137.17 with a market capitalization of $14. This page provides 41 historical financial statements for Neurocrine Biosciences Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Neurocrine Biosciences Inc reported revenue of $2.9 billion, representing 21.4% year-over-year growth. The net profit margin of 16.7% reflects strong profitability..
NBIX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Neurocrine Biosciences Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether NBIX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track NBIX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Neurocrine Biosciences Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of NBIX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use NBIX Financial Data
Investors use Neurocrine Biosciences Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare NBIX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how NBIX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View NBIX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Neurocrine Biosciences Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.NBIX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.